What you should know:
1. NuVasive has improved on its core X360 platform as well as its Pulse robotics platform.
2. Since June, the company’s shares have increased some 35 percent.
3. Seeking Alpha’s analyst was bullish on NuVasive’s near-to-medium-term future because of the advances behind the company’s two platforms.
4. The analyst is optimistic about 2020 and 2021 and the company’s long term future, increasing his performance expectations through 2028.
More articles on orthopedics and spine:
Zimmer Biomet in 2019: 6 things to know
How Stryker plans to grow Mako — 4 insights from chief technology officer Robert Cohen
Medtronic Spine 2019: The year in review
